期刊文献+
共找到1篇文章
< 1 >
每页显示 20 50 100
Application and Research Advancement of Antibody-Conjugated Drugs in Non-Small Cell Lung Cancer
1
作者 Binting Huang Kaifang li +2 位作者 Xiangsheng Wu Fuyi Zhang yepeng li 《Journal of Biosciences and Medicines》 2025年第1期145-162,共18页
Lung cancer is one of the malignant tumor diseases with high morbidity and high mortality in the world. Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer. Currently, chemotherapy, ... Lung cancer is one of the malignant tumor diseases with high morbidity and high mortality in the world. Non-small cell lung cancer (NSCLC) is the most common pathological type of lung cancer. Currently, chemotherapy, targeted therapy, immunotherapy or combination therapy is the main treatment for NSCLC, but it is still inevitably faced with the challenges of acquired drug resistance and tumor progression. The birth of antibody conjugator provides a new choice for its treatment. Antibody conjugator is a new type of biotherapeutic drug which is connected by monoclonal antibody via linker and cytotoxic drug. It has the characteristics of precision, high efficiency and low toxicity, etc. In recent years, its research and development and clinical trials have been endless. It shows that this new type of drug has great potential in the field of tumor therapy. In this paper, the structural characteristics, mechanism of action, current application, research achievements, challenges, countermeasures and development of ADC in NSCLC treatment are reviewed. 展开更多
关键词 Non-Small Cell Lung Cancer Antibody Coupling Drugs Combination Therapy Adverse Reaction
在线阅读 下载PDF
上一页 1 下一页 到第
使用帮助 返回顶部